The Problem

Canada’s health system is at a defining moment. Global changes in how medicines are priced and valued have exposed a critical vulnerability: Canada is not investing enough in health innovation.

While other countries have strengthened their life sciences sectors, Canada has relied on the status quo. As a result, we are less prepared for the global changes now under way.

These changes are already influencing which countries gain access to new medicines—and which are left behind. If Canada does not respond, Canadians risk losing access to life – saving treatments.

At the same time, research investment and clinical trials will move elsewhere, weakening our life sciences sector and the economy.

This is not a future we can afford.

The Problem

Canada’s health system is at a defining moment. Global changes in how medicines are priced and valued have exposed a critical vulnerability: Canada is not investing enough in health innovation.

While other countries have strengthened their life sciences sectors, Canada has relied on the status quo. As a result, we are less prepared for the global changes now under way.

These changes are already influencing which countries gain access to new medicines—and which are left behind. If Canada does not respond, Canadians risk losing access to life – saving treatments.

At the same time, research investment and clinical trials will move elsewhere, weakening our life sciences sector and the economy.

This is not a future we can afford.

By signing up, you agree to receive periodic emails from Medicine Matters Canada containing news, updates, and ways to get involved. Medicine Matters Canada is an initiative of Innovative Medicines Canada (“IMC”). These emails may be sent on IMC’s behalf by our service provider. You can unsubscribe at any time. Contact: Innovative Medicines Canada | 310-99 rue Bank St. Ottawa, ON K1P 6B9 | info@imc-mnc.ca